echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Everything you want to know about bevacizumab is here!

    Everything you want to know about bevacizumab is here!

    • Last Update: 2023-01-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Bevacizumab is a recombinant humanized monoclonal antibody that inhibits VEGF binding to its receptors by specifically targeting human vascular endothelial growth factor (VEGF), inhibits the formation of tumor blood vessels, reduces the supply of blood, oxygen and other nutrients to tumors, thereby inhibiting tumor cell growth
    .
    Bevacizumab was approved by the U.
    S.
    Food and Drug Administration in 2004 and entered the Chinese market
    in 2010.
    As one of the important drugs for anti-tumor angiogenesis, bevacizumab has been used in the treatment
    of a variety of malignant tumors.
    1.
    Applicable diseases

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.